Matches in Wikidata for { <http://www.wikidata.org/entity/Q63571132> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q63571132 description "clinical trial" @default.
- Q63571132 description "ensayu clínicu" @default.
- Q63571132 description "klinisch onderzoek" @default.
- Q63571132 description "клінічне випробування" @default.
- Q63571132 name "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors" @default.
- Q63571132 type Item @default.
- Q63571132 label "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors" @default.
- Q63571132 prefLabel "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors" @default.
- Q63571132 P1132 Q63571132-0462D086-156B-4662-AA21-E2DFC3FF70AF @default.
- Q63571132 P1476 Q63571132-B04D29B8-306E-4D5D-9D7A-0591197275C0 @default.
- Q63571132 P17 Q63571132-BD1E35C6-0E49-4906-BA47-BEBF8A1111D1 @default.
- Q63571132 P1813 Q63571132-2C764565-0889-44F3-BAAA-236F7A7C5FEB @default.
- Q63571132 P2899 Q63571132-D31B0685-C019-4AEF-B193-F5DEE97F55C0 @default.
- Q63571132 P3098 Q63571132-C2300677-DE48-4E44-95B0-6ED1F25D63CE @default.
- Q63571132 P31 Q63571132-C0325E1B-CB51-44B5-8F5C-6201012E0E13 @default.
- Q63571132 P4844 Q63571132-4B1B0926-45C0-46C4-B914-507D91BC0A6C @default.
- Q63571132 P580 Q63571132-EC7CCE43-CD92-45E6-AF43-21BDA9315DE4 @default.
- Q63571132 P582 Q63571132-5FA6342B-AC9B-4D2B-B79C-CDC780274201 @default.
- Q63571132 P6099 Q63571132-9315D92B-538F-4DD0-8011-F1BC72FBC16C @default.
- Q63571132 P6153 Q63571132-2269C2B1-1E9E-4A8F-A147-469447DD90BA @default.
- Q63571132 P6153 Q63571132-234D73F8-3512-4067-894F-F85D5393B79E @default.
- Q63571132 P6153 Q63571132-7D5C5B34-B358-467E-9F8F-6CE12D6C2F2B @default.
- Q63571132 P6153 Q63571132-A0A3F1F3-FE63-453E-BB67-9DC4245B5FC4 @default.
- Q63571132 P8363 Q63571132-245D106E-3189-4F28-AF13-DE1C050BBA23 @default.
- Q63571132 P1132 "+90" @default.
- Q63571132 P1476 "A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors" @default.
- Q63571132 P17 Q30 @default.
- Q63571132 P1813 "KEYNOTE-603" @default.
- Q63571132 P2899 "+18" @default.
- Q63571132 P3098 "NCT03313778" @default.
- Q63571132 P31 Q30612 @default.
- Q63571132 P4844 Q13896859 @default.
- Q63571132 P580 "2017-08-14T00:00:00Z" @default.
- Q63571132 P582 "2019-09-01T00:00:00Z" @default.
- Q63571132 P6099 Q5452194 @default.
- Q63571132 P6153 Q126412 @default.
- Q63571132 P6153 Q4892499 @default.
- Q63571132 P6153 Q503419 @default.
- Q63571132 P6153 Q5637237 @default.
- Q63571132 P8363 Q78089383 @default.